Animal models for the study of squamous cell carcinoma of the upper aerodigestive tract: A historical perspective with review of their utility and limitations. Part A. Chemically-induced de novo cancer, syngeneic animal models of HNSCC, animal models of transplanted xenogeneic human tumors

International Journal of Cancer

Volumn 118, Issue 9, 2006, Pages 2111-2122

  Smith, Lee P ^a   Thomas, Giovana R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; ANTISENSE OLIGONUCLEOTIDE; CELECOXIB; CISPLATIN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2 INHIBITOR; E1A PROTEIN; ETODOLAC; FLUCYTOSINE; FLUOROURACIL; FUSARIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; IRINOTECAN; NIMESULIDE; PROBUCOL; RALTITREXED; RETINOIC ACID; SCATTER FACTOR; SCUTELLARIA BAICALENSIS EXTRACT; SODIUM IODIDE SYMPORTER; STAT3 PROTEIN; TROGLITAZONE; TUMOR CELL VACCINE; TUNICAMYCIN; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER TRANSPLANTATION; CARCINOGENESIS; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; TREATMENT INDICATION; TREATMENT OUTCOME;

ANIMALS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; HEAD AND NECK NEOPLASMS; HISTORY, 20TH CENTURY; HUMANS; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 33645697665     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21694     Document Type: Short Survey

References (166)

1. Goldberg HI, Lockwood SA, Wyatt SW, Crossett LS. Trends and differentials in mortality from cancers of the oral cavity and pharynx in the United States, 1973-1987. Cancer 1994;74:565-72.
2. Boone CW, Steele VE, Kelloff GJ. Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutat Res 1992;267:251-5.
3. Eveson JW. Animal models of intra-oral chemical carcinogenesis: a review. J Oral Pathol 1981;10:129-46.
4. Salley JJ. Experimental carcinogenesis in the cheek pouch of the Syrian hamster. J Dent Res 1954;33:253-62.
5. Gimenez-Conti IB, Slaga TJ. The hamster cheek pouch carcinogenesis model. J Cell Biochem Suppl 1993;17F:83-90.
6. Fisker AV. Experimental oral carcinogenesis. A basic rat model for the study of oral carcinogenesis using the carcinogen 4-nitroquinoline 1-oxide. Dan Med Bull 1990;37:433-42.
7. Morris AL. Factors influencing experimental carcinogenesis in the hamster cheek pouch. J Dent Res 1961;40:3-15.
8. Slaga TJ, Gimenez-Conti IB. An animal model for oral cancer. J Natl Cancer Inst Monogr 1992;13:55-60.
9. Nishimura N, Urade M, Hashitani S, Moguchi K, Manno Y, Takaoka K, Sakurai K. DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med 2004;33:614-21.
10. Chang KW, Lin SC, Koos S, Pather K, Solt D. p53 and Ha-ras mutations in chemically induced hamster buccal pouch carcinomas. Carcinogenesis 1996;17:595-600.
11. Gimenez-Conti IB, LaBate M, Liu F, Osterndorff E. p53 alterations in chemically induced hamster cheek-pouch lesions. Mol Carcinog 1996;16:197-202.
12. Chen YK, Lin LM. Sequential expression of placental glutathione S-transferase (GST-P) during DMBA-induced hamster buccal pouch squamous cell carcinogenesis. J Oral Pathol Med 1996;25:388-94.
13. Iida K, Yamamoto M, Kato M, Yoshida K, Kurita K, Tatematsu M. Strong expression of glutathione S-transferase placental form in early preneoplastic lesions and decrease with progression in hamster buccal pouch carcinogenesis. Cancer Lett 1999;135:129-36.
14. Lingen MW, DiPietro LA, Solt DB, Bouck NP, Polverini PJ. The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFbeta-1 and is unaffected by ras activation. Carcinogenesis 1997;18:329-38.
15. Zenklusen JC, Stockman SL, Fischer SM, Conti CJ, Gimenez-Conti IB. Transforming growth factor-beta 1 expression in Syrian hamster cheek pouch carcinogenesis. Mol Carcinog 1994;9:10-6.
16. Lee SK, Park SC, Chi JG, Sakamoto F, Shrestha P, Mori M. Expression of tenascin in hamster buccal pouch mucosa during experimental carcinogenesis. Eur J Cancer B Oral Oncol 1995;31B(3):188-92.
17. Urade M, Uematsu T, Mima T, Ogura T, Matsuya T. Serum dipeptidyl peptidase (DPP) IV activity in hamster buccal pouch carcinogenesis with 9,10-dimethyl-1,2-benzanthracene. J Oral Pathol Med 1992;21:109-112.
18. Shin DM, Chiao PJ, Sacks PG, Shin HJ, Hong WK, Hittelman WN, Tainsky MA. Activation of ribosomal protein S2 gene expression in a hamster model of chemically induced oral carcinogenesis. Carcinogenesis 1993;14:163-6.
19. Balasubramanian S, Elangovan V, Govindasamy S. Flourescence spectroscopic identification of 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Carcinogenesis 1995;16:2461-5.
20. Dhingra JK, Zhang X, McMillan K, Kabani S, Manoharan R, Itzkan I, Feld MS, Shapshay SM. Diagnosis of head and neck precancerous lesions in an animal model using fluorescence spectroscopy. Laryngoscope 1998;108(4 Pt 1):471-5.
21. Pathak I, Davis NL, Hsiang YN, Quenville NF, Palcic B. Detection of squamous neoplasia by fluorescence imaging comparing porfimer sodium fluorescence to tissue autofluorescence in Ihe hamster cheek-pouch model. Am J Surg 1995;170:423-6.
22. Borle F, Radu A, Fontolliet C, van den Bergh H, Monnier P, Wagnieres G. Selectivity of the photosensitiser Tookad for photodynamic therapy evaluated in the Syrian golden hamster cheek pouch tomour model. Br J Cancer 2003;89:2320-6.
23. Wang Z, Polavaram R, Fuentes CF, Shapshay SM. Topical chemoprevention of oral cancer with tretinoin "biofilm". Arch Otolaryngol Head Neck Surg 2003;129:869-73.
24. Miller EG, Gonzales-Sanders AP, Couvillon AM, Wright JM, Hasegawa S, Lam LK. Inhibition of hamster buccal pouch carcinogenesis by limonin 17-beta-D-glucopyranoside. Nutr Cancer 1992;17:1-7.
25. Balasenthil S, Arivazhagan S, Ramachandran CR, Nagini S. Effects of garlic on 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Cancer Detect Prev 1999;23:534-8.
26. Nagabhushan M, Line D, Polverini PJ, Solt DB. Anticarcinogenic action of diallyl sulfide in hamster buccal pouch and forestomach. Cancer Lett 1992;66:207-16.
27. Schwartz JL, Shklar G. Glutathione inhibits experimental oral carcinogenesis, p53 expression, and angiogenesis. Nutr Cancer 1996;26:229-36.
28. Balasenthil S, Arivazhagan S, Ramachandran CR, Ramachandran V, Nagini S. Chemopreventive potential of neem (Azadirachta indica) on 7,12-dimethylbenz[a] anthracene (DMBA) induced hamster buccal pouch carcinogenesis. J Ethnopharmacol 1999;67:189-95.
29. Karthikeyan K, Ravichandran P, Govindasamy S. Chemopreventive effect of Ocimum sanctum on DMBA-induced hamster buccal pouch carcinogenesis. Oral Oncol 1999;35:112-9.
30. Balasubramanian S, Govindasamy S. Inhibitory effect of dietary flavonol quercetin on 7,12-dimethylbenz|a|anthracene-induced hamster buccal pouch carcinogenesis. Carcinogenesis 1996;17:877-9.
31. Casto BC, Kresty LA, Kraly CL, Pearl DK, Knobloch TJ, Schut HA, Stoner GD, Mallery SR, Weghorst CM. Chemoprevention of oral cancer by black raspberries. Anticancer Res 2002;22(6C):4005-15.
32. Bhuvaneswari V, Velmurugan B, Nagini S. Dose-response effect of tomato paste on 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. J Exp Clin Cancer Res 2004;23:241-9.
33. Jin YT, Tsai ST, Wong TY, Chen FF, Chen RM. Studies on promoting activity of Taiwan betel quid ingredients in hamster cheek pouch carcinogenesis. Eur J Cancer B Oral Oncol 1996;32B(5):343-6.
34. Lin LM, Chen YK, Lai DR, Huang YL, Chen HR. Cancer-promoting effect of Taiwan betel quid in hamster cheek pouch carcinogenesis. Oral Dis 1997;3:232-5.
35. Harada K, Yura Y, Tsujimoto H, Kusaka J, Yoshida H, Sato M. Effect of local administration of epidermal growth factor on 9,10-dimethyl-1,2- benzanthracene-induced tumour formation in hamsler cheek pouch. Eur J Cancer B Oral Oncol 1995;31:27-31.
36. Tang X, Knudson B, Bemis D, Tickoo S, Gudas LJ. Oral cavity and esophaaeal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res 2004;10:301-13.
37. Yuan B, Hu LH, Lentsch EM, Shum-Siu A, Hendler FJ. Consistent allelic loss on mouse chromosome 7 distal to tyrosinase in 4-nitroquinoline-1-oxide- induced oral cavity tumors with loss of heterozygosity at Ha-ras-1. Mol Carcinog 1997;19:8-16.
38. Game SM, Stone A, Scully C, Prime SS. Tumour progression in experimental oral carcinogenesis is associated with changes in EGF and TGF-beta receptor expression and altered responses to these growth factors. Carcinogenesis 1990;11:965-73.
39. Ma G, Ikeda H, Inokuchi T, Sano K. Effect of photodynamic therapy using 5-aminolevulinic acid on 4-nitroquinoline-1-oxide-induced premalignant and malignant lesions of mouse tongue. Oral Oncol 1999;35:120-4.
40. Park K, Yang JH, Choi Y, Lee C, Kim SY, Byun Y. Chemoprevention of 4-NQO-induced oral carcinogenesis by co-administration of all-trans retinoic acid loaded microspheres and celecoxib. J Control Release 2005;104:167-79.
41. Yamamoto K, Kitayama W, Denda A, Morisaki A, Kuniyasu H, Inoue M, Kirita T. Suppressive effects of a selective cyclooxygenase-2 inhibitor, etodolac, on 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Exp Toxicol Pathol 2004;56:145-51.
42. Yoshida K, Hirose Y, Tanaka T, Yamada Y, Kuno T, Kohno H, Katayama M, Qiao Z, Sakata K, Sugie S, Shibata T, Mori H. Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide. Cancer Sci 2003;94:365-71.
43. Shiotani H, Denda A, Yamamoto K, Kitayama W, Endoh T, Sasaki Y, Tsutsumi N, Sugimura M, Konishi Y Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and Chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 2001;61:1451-6
44. Johansson SL, Hirsch JM, Larsson PA, Saidi J, Osterdahl BG. Snuff-induced carcinogenesis: effect of snuff in rats initiated with 4-nitroquinoline N-oxide. Cancer Res 1989;49:3063-9.
45. Steidler NE, Reade PC. Experimental induction of oral squamous cell carcinomas in mice with 4-nitroquinolone-1-oxide. Oral Surg Oral Med Oral Pathol 1984;57:524-31.
46. Fields MT, Eisbruch A, Normolle D, Orfali A, Davis MA, Pu AT, Lawrence TS Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys 2000;47:785-91.
47. Thomas DW, Mathews JB, Patel V, Game SM, Prime SS. Inflammatory cell infiltrate associated with primary and transplanted tumours in an inbred model of oral carcinogenesis. J Oral Pathol Med 1995;24:23-31.
48. Noda I, Fujieda S, Seki M, Tanaka N, Sunaga H, Ohtsubo T, Tsuzuki H, Fan GK, Saito H. Inhibition of N-linked glycosylation by tunicamycin enhances sensitivity to cisplatin in human head-and-neck carcinoma cells. Int J Cancer 1999;80:279-84.
49. Myers JN, Mank-Seymour A, Zitvogel L, Storkus W, Clarke M, Johnson CS, Tahara H, Lotze MT. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope 1998;108:261-8.
50. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997;57:3759-64.
51. Scioscia KA, Snyderman CH, Rueger R, Reddy J, D'Amico F, Comsa S, Collins B. Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinflammatory drugs. Am J Otolaryngol 1997;18:1-8.
52. Grandis JR, Chang MJ, Yu WD, Johnson CS. Antitumor activity of interleukin-l alpha and cisplatin in a murine model system. Arch Otolaryngol Head Neck Surg 1995;121:197-200.
53. Couch M, Saunders JK, O'Malley BW Jr., Pardoll D, Jaffee E. Genetically engineered tumor cell vaccine in a head and neck cancer model. Laryngoscope 2003;113:552-6.
54. Dasgupta S, Tripathi PK, Bhattacharya-Chatterjee M, O'Malley B Jr., Chatterjee SK. Recombinant vaccinia virus expressing IL-2 generates effective anti-tumor responses in an orthotopic murine model of head and neck carcinoma. Mol Ther. 2003;8(2):238-48.
55. Hamstra DA, Rice DJ, Fahmy S, Ross BD, Rehemtulla A. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Then 1999;10(12):1993-2003.
56. Li D, Jiang W, Bishop JS, Ralston R, O'Malley BW, Jr. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer. Clin Cancer Res. 1999;5(6):1551-6.
57. O'Malley BW Jr., Sewell DA, Li D, Kosai K, Chen SH, Woo SL, Duan L. The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol Endocrinol 1997;11:667-73.
58. Lou E, Kellman RM, Shillitoe EJ. Effect of herpes simplex virus type-1 on growth of oral cancer in an immunocompetent, orthotopic mouse model. Oral Oncol 2002;38:349-56.
59. Stack BC Jr., Hansen JP, Ruda JM, Jaglowski J, Shvidler J, Hollenbeak CS. Fusaric acid: a novel agent and mechanism to treat HNSCC. Otolaryngol Head Neck Surg 2004;131:54-60.
60. Cao S, McGuire JJ, Rustum YM. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. Clin Cancer Res 1999;5:1925-34.
61. Nishimura G, Yanoma S, Mizuno H, Kawakami K, Tsukuda M. An antioxidant, probucol, induces anti-angiogenesis and apoptosis in athymic nude mouse xenografted human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999;90:1224-30.
62. Zhang DY, Wu J, Ye F, Xue L, Jiang S, Yi J, Zhang W, Wei H, Sung M, Wang W, Li X. Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baiculensis. Cancer Res 2003;63:4037-43.
63. Choi Y, Kim SY, Kim SH, Yang J, Park K, Byun Y. Inhibition of tumor growth by biodegradable microspheres containing all-trans-retinoic acid in a human head-and-neck cancer xenograft. Int J Cancer 2003;107:145-148.
64. Wang Z, Feuntes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 2002;112:839-43.
65. Zacheis D, Dhar A, Lu S, Madler MM, Klucik J, Brown CW, Liu S, Clement F, Subramanian S, Weerasekare GM, Berlin KD, Gold MA, et al. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J Med Chem 1999;42:4434-45.
66. Moritani NH, Kubota S, Nishida T, Kawaki H, Kondo S, Sugahara T, Takigawa M. Suppressive effect of overexpressed connective tissue growth factor on tumor cell growth in a human oral squamous cell carcinoma-derived cell line. Cancer Lett 2003;192:205-14.
67. Zeng Q, McCauley LK, Wang CY. Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. J Biol Chem 2002;277:50137-42.
68. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 2002;62:6706-11.
69. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000;97:4227-32.
70. Riedel F, Gotte K, Hormann K, Grandis JR. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy. Adv Otorhinolaryngol 2005;62:103-20.
71. Azrak RG, Cao S, Slocum HK, Toth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 2004;10:1121-9.
72. Gaut AW, Niu G, Krager KJ, Graham MM, Trask DK, Domann FE. Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS). Head Neck 2004;26:265-71.
73. Kanazawa T, Mizukami H, Okada T, Hanazono Y, Kume A, Nishino H, Takeuchi K, Kitamura K, Ichimura K, Ozawa K. Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther 2003;10:51-8.
74. Niwa H, Wentzel AL, Li M, Gooding WE, Lui VW, Grandis JR. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res 2003;9:5028-35.
75. Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L, Hung MC. Systemic gene therapy in human xenoaraft tumor models by liposomal delivery of the E1A gene. Cancer Res 2002;62:6712-6.
76. Kawakami K, Husain SR, Kawakami M, Puri RK. Improved antitumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Mol Med 2002;8:487-94.
77. Sommer K, Peters SO, Robins IH, Raap M, Wiedemann GJ, Remmert S, Sieg P, Bittner C, Feyerabend T. A preclinical model for experimental chemotherapy of human head and neck cancer. Int J Oncol 2001;18:1145-9.
78. Tandy JR, Tandy RD, Farris P, Truelson JM. In vivo interaction of cis-platinum and fosfomycin on squamous cell carcinoma. Laryngoscope 2000;110:1222-4.
79. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Abra RM, Stewart JS. Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer 2000;83:232-8.
80. Shikani AH, Domb AJ. Polymer chemotherapy for head and neck cancer. Laryngoscope 2000;110:907-17.
81. Endo S, Zeng Q, Burke NA, He Y, Melhem MF, Watkins SF, Lango MN, Drenning SD, Huang L, Rubin Grandis J. TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo. Gene Ther 2000;7:1906-14.
82. Sengupta S, Ralhan R, Wasylyk B. Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53. Oncogene 2000;19:337-50.
83. Chen FA, Kuriakose MA, Zhou MX, DeLacure MD, Dunn RL. Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model. Head Neck 2003;25:554-60.
84. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-53.
85. Sauter ER, Herlyn M, Liu SC, Litwin S, Ridge JA. Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model. Clin Cancer Res 2000;6:654-60.
86. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, Siebenlist U, Van Waes C. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999;59:3468-74.
87. Zhang SY, Liu SC, Johnson DG, Klein-Szanto AJ. E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. Cancer Res 2000;60:5972-6.
88. Soukka T, Salmi M, Joensuu H, Hakkinen L, Sointu P, Koulu L, Kalimo K, Klemi P, Grenman R, Jalkanen S. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res 1997;57:2281-9.
89. Burch JD, Howe GR, Miller AB, Semenciw R. Tobacco, alcohol, asbestos, and nickel in the etiology of cancer of the larynx: a case-control study. J Natl Cancer Inst. 1981;67:1219-24.
90. Spitz MR, Fueger JJ, Goepfert H, Hong WK, Newell GR. Squamous cell carcinoma of the upper aerodigestive tract. A case comparison analysis. Cancer 1988;61:203-208.
91. Shklar G, Eisenberg E, Flynn E. Immunoenhancing agents and experimental leukoplakia and carcinoma of the hamster buccal pouch. Prog Exp Tumor Res 1979;24:269-282.
92. Kim TW, Chen Q, Shen X, Regezi JA, Ramos DM, Tanaka H, Jordan RC, Kramer RH. Oral mucosal carcinogenesis in SENCAR mice. Anticancer Res 2002;22:2733-40.
93. Heller B, Kluftinger AM, Davis NL, Quenville NF. A modified method of carcinogenesis induction in the DMBA hamster cheek pouch model of squamous neoplasia. Am J Surg 1996;172:678-80.
94. MacDonald DG. A technique for localization of tumours in hamster cheek-pouch carcinogenesis. Arch Oral Biol 1978;23:573-7.
95. Cannell H. Experimental intra-oral carcinoma. J Maxillofac Surg 1979;7:165-71.
96. MacDonald DG. Comparison of epithelial dysplasia in hamster cheek pouch carcinogenesis and human oral mucosa. J Oral Pathol 1981;10:186-91.
97. Wallenius K, Lekholm U. Influence of saliva on epidermal cancer in rat induced by water-or fat soluble carcinogens. Odontol Revy 1973;24:115-26.
98. Eveson JW, MacDonald DG. Hamster tongue carcinogenesis 1. Characteristics of the experimental model. J Oral Pathol 1981;10:322-31.
99. Schwartz JL, Gu X, Kittles RA, Baptiste A, Shklar G. Experimental oral carcinoma of the tongue and buccal mucosa: possible biologic markers linked to cancers at two anatomic sites. Oral Oncol 2000;36:225-35.
100. Omura S, Tsuyuki Y, Ohta S, Bukawa H, Fujita K. In vivo antitumor effects of electrochemotherapy in a tongue cancer model. J Oral Maxillofac Surg 1999;57:965-72.
101. Goodwin WJ, Bordash GD, Xue JW, Huijing F, Altman N. Selenium inhibition of chemical carcinogenesis in the upper aerodigestive tract of hamsters. Otolaryngol Head Neck Surg 1985;93:373-9.
102. Goodwin WJ, Bordash GD, Huijing F, Altman N. Inhibition of hamster tongue carcinogenesis by selenium and retinoic acid. Ann Otol Rhinol Laryngol 1986;95(2Pt 1):162-6.
103. Shklar G, Flynn E, Szabo G, Marefat P. Retinoid inhibition of experimental lingual carcinogenesis: ultrastructural observations. J Natl Cancer Inst 1980;65:1307-16.
104. Hidaka S, Morita N, Ohnishi ST, Oga Y, Abe K. Inhibitory effect of prostaglandin oligomeric derivatives on 9,10-dimethyl-1,2-benzathracene-induced hamster lingual carcinomas. Cancer Lett 1992;61:171-6.
105. Iwasaki T, Maeda H, Kameyama Y, Moriyama M, Kanai S, Kurata T. Presence of a novel hamster oral papillomavirus in dysplastic lesions of hamster lingual mucosa induced by application of dimethylbenzathracene and excisional wounding: molecular cloning and complete nucleotide sequence. J Gen Virol 1997;78(Pt 5):1087-93.
106. Maeda H, Kameyama Y, Nakane S, Takehana S, Sato E. Epithelial dysplasia produced by carcinogen pretreatment and subsequent wounding. Oral Surg Oral Med Oral Pathol 1989;6:50-6.
107. Wong PN, Wilson DF. 4 Nitroquinoline 1-oxide-induced carcinogenesis in the rat palate. J Oral Pathol 1983;12:375-84.
108. Nauta JM, van Leengoed HL, Witjes MJ, Nikkels PG, Star WM, Vermey A, Roodenburg JL. Photofrin-mediated photodynamic therapy of chemically-induced premalignant lesions and squamous cell carcinoma of the palatal mucosa in rats. Int J Oral Maxillofac Surg 1997;26:223-31.
109. Nauta JM, Roodenburg JL, Nikkels PG, Witjes MJ, Vermey A. Comparison of epithelial dysplasia-the 4NQO rat palate model and human oral mucosa. Int J Oral Maxillofac Surg 1995;24(1 Pt 1):53-8.
110. Booth DR. A relationship found between intra-oral sites of 4NQO reductase activity and chemical carcinogenesis. Cell Tissue Kinet 1990;23:331-40.
111. Jiang DJ, Wilson DF, Wiebkin OW. Ultrastructural features of normal epithelium and 4-nitroquinoline 1-oxide-induced carcinomas of the rat tongue. J Comp Pathol 1993;108:375-81.
112. Dayan D, Hirshberg A, Kaplan I, Rotem N, Bodner L. Experimental tongue cancer in desalivated rats. Oral Oncol 1997;33:105-9.
113. Itoh T, Yamamoto Y, Saka T, Inoue I, Takahashi H. Estimation of proliferative activity of experimental tongue carcinoma in rats. Immunohistochemical and DNA cytofluorometric analysis. Acta Otolaryngol 1993;113:568-74.
114. Kaplan I, Engelberg J, Dayan D. The effect of desalivation on 4-nitroquinoline-1-oxide-induced tongue carcinogenesis: a morphometric study of nucleolar organizer regions. J Oral Pathol Med 2001;30:48-52.
115. Nauta JM, Roodenburg JL, Nikkels PG, Witjes MJ, Vermey A. Epithelial dysplasia and squamous cell carcinoma of the Wistar rat palatal mucosa: 4NQO model. Head Neck 1996;18:441-9.
116. Hawkins BL, Heniford BW, Ackermann DM, Leonberger M, Martinez SA, Hendler FJ. 4NQO carcinogenesis: a mouse model of oral cavity squamous cell carcinoma. Head Neck 1994;16:424-32.
117. Ribeiro DA, Favero Salvadori DM, da Silva RN, Ribeiro Darros B, Alencar Marques ME. Genomic instability in non-neoplastic oral mucosa cells can predict risk during 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Oral Oncol 2004;40:910-5.
118. 2 laser and scalpel incision on 4-NQO-induced premalignant lesions of mouse tongue. Lasers Surg Med 1999;25:207-12.
119. Fu KK, Rayner PA, Lam KN. Modification of the effects of continuous low dose rale irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys 1984;10:1473-8.
120. O'Malley BW, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997;123:20-4.
121. Hier MP, Black MJ, Shenouda G, Sadeghi N, Karp SE. A murine model for the immunotherapy of head and neck squamous cell carcinoma. Laryngoscope 1995;105:1077-80.
122. Thomas GR, Chen Z, Oechsli MN, Hendler FJ, Van Waes C. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int J Cancer 1999;82:377-84.
123. Thomas GR, Chen Z, Enamorado I, Bancroft C, Van Haes C. IL-12- and IL-2-induced tumor regression in a new murine model of oral squamous-cell carcinoma is promoted by expression of the CD80 costimulatory molecule and interferon-γ. Int J Cancer 2000;86:368-74.
124. Prudencio J, Akutsu N, Benlimame N, Wang T, Bastien Y, Lin R, Black MJ, Alaoui-Jamali MA, White JH. Action of low calcemic 1alpha,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma. J Natl Cancer Inst 2001;93:745-53.
125. Sumareva R, Ukrainsky G, Kiremidjian-Schumacher L, Roy M, Wishe HI, Steinfeld AD, Cooper JS. Effect of combined adoptive immunotherapy and radiotherapy on tumor growth. Radiat Oncol Investig 1999;7:22-9.
126. Gleich LL, Li YQ, Li S, Gluckman JL, Stambrook PJ. Alloantigen gene therapy for head and neck cancer: evaluation of animal models. Head Neck 2003;25:274-9.
127. Dinesman A, Haughey B, Gates GA, Aufdemorte T, Von Hoff DD. Development of a new in vivo model for head and neck cancer. Otolaryngol Head Neck Surg 1990;103(5 Pt 1):766-74.
128. Lou E, Kellman RM, Hutchison R, Shillitoe EJ. Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. Oral Dis 2003;9:305-12.
129. Hamstra DA, Rice DJ, Pu A, Oyedijo D, Ross BD, Rehemtulla A. Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model. Radiat Res 1999;152:499-507.
130. Fantozzi R, Bone R, Fernsten P, Walker L. Upper aerodigestive neoplasm perpetuated in the nude mouse. Laryngoscope 1986;96:621-4.
131. Baker SR. An in vivo model for squamous cell carcinoma of the head and neck. Laryngoscope 1985;95:43-56.
132. Povlsen CO, Rygaard J. Heterotransplantation of human epidermoid carcinomas to the mouse mutant nude. Acta Pathol Microbiol Scand A 1972;80:713-7.
133. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527-30.
134. Fiebig HH, Berger DP, Dengler WA, Wallbrecher E, Winterhalter BR. Combined in vitrolin vivo lest procedure with human tumor xenografts. In: Fiebig HH, Bereger DP, eds. Immunodeficient Mice in Oncology. Contributions in Oncolgy, Vol 42. Basel: Karger, 1992;321-51.
135. Fiebig H. T-cell reactivity of modified allergens. Allergy 1999;54(Suppl 56):33-4.
136. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004;40:827-36.
137. Braakhuis BJ, van Dongen GA, Bagnay M, van Walsum M, Snow GB. Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude mice. Head Neck 1989;11:511-5.
138. Boven E, Winograd B, Berger DP, Dumont MP, Braakhuis BJ, Fodstad O, Langdon S, Fiebig HH. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res. 1992;52:5940-7.
139. van Dongen G, Braakhuis BJ, Bagnay M, Leyva A, Snow GB. Activity of differentiation-inducing agents and conventional drugs in head and neck cancer xenografts. Acta Otolaryngol 1988;105:488-93.
140. Sharkey FE, Fogh J. Metastasis of human tumors in athymic nude mice. Int J Cancer 1979;24:733-8.
141. Hanna N, Fidler IJ. Expression of metastatic potential of allogenic and xenogeneic neoplasms in young nude mice. Cancer Res 1981;41:438-44.
142. Braakhuis BJ, Sneeuwloper G, Snow GB. The potential of the nude mouse xenograft model for the study of head and neck cancer. Arch Otorhinolaryngol 1984;239:69-79.
143. Fitch KA, Somers KD, Schechter GL. The development of a head and neck tumor model in the nude mouse. In: Wolf GT, Walker CT, eds. Head and neck oncology research. Amsterdam: Kugler & Ghedini, 1988, 187-90.
144. Sales EW, Fitch KA, Sudetic PA, Schechter GL, Faulconer RJ, Somers KD. Growth and histopathology of human head and neck squamous cell carcinoma implanted intraorally in nude mice. Otolaryngol Head Neck Surg 1991;104:351-7.
145. Kawashiri S, Kumagai S, Kojima K, Harada H, Yamamoto E. Development of a new invasion and metastasis model of human oral squamous cell carcinomas. Eur J Cancer B Oral Oncol 1995;31:216-21.
146. Kawashiri S, Kumagai S, Kojima K, Harada H, Nakagawa K, Yamamoto E. Reproduction of occult metastasis of head and neck cancer in nude mice. Clin Exp Metastasis 1999;17:277-82.
147. Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler U. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res 2002;8:293-8.
148. Shintani S, Mihara M, Nakahara Y, Aida T, Tachikawa T, Hamakawa H. Lymph node metastasis of oral cancer visualized in live tissue by green fluorescent protein expression. Oral Oncol 2002;38:664-9.
149. Yamashita T, Fujii M, Tomita T, Ishiguro R, Tashiro M, Tokumaru Y, Imanishi Y, Kanke M, Ogawa K, Kameyama K, Otani Y. The inhibitory effect of matrix metalloproteinase inhibitor ONO-4817 on lymph node metastasis in tongue carcinoma. Anticancer Res 2003;23(3B):2297-302.
150. Maekawa K, Sato H, Furukawa M, Yoshizaki T. Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model. Clin Exp Metastasis 2002;19:513-8.
151. Noguchi N, Kawashiri S, Tanaka A, Kato K, Nakaya H. Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma. Oral Oncol 2003;39:240-7.
152. Holsinger FC, Doan DD, Jasser SA, Swan EA, Greenberg JS, Schiff BA, Bekele BN, Younes MN, Bucana CD, Fidler IJ, Myers JN. Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 2003;9:3183-9.
153. Prime SS, Eveson JW, Stone AM, Huntley SP, Davies M, Paterson IC, Robinson CM. Metastatic dissemination of human malignant oral keratinocyte cell lines following orthotopic transplantation reflects response to TGF-beta 1. J Pathol 2004;203:927-32.
154. Bosma GC, Davisson MT, Ruetsch NR, Sweet HO, Shultz LD, Bosma MJ. The mouse mutation severe combined immune deficiency (SCID) is on chromosome 16. Immunogenetics 1989;29:54-7.
155. Custer RP, Bosma GC, Bosma MJ. Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution, neoplasms. Am J Pathol 1985;120:464-77.
156. Dorshkind K, Keller GM, Phillips RA, Miller RG, Bosnia GC, O'Toole M, Bosma MJ. Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease. J Immunol 1984;132:1804-8.
157. Kurokawa H, Katsube K, Podyma KA, Ikuta M, Iseki H, Nakajima M, Akashi T, Omura K, Takagi M, Yanagrshita M. Heparanase and tumor invasion patterns in human oral squamous cell carcinoma xenografts. Cancer Sci 2003;94:277-85.
158. Phillips RA, Jewett MA, Gallic BL. Growth of human tumors in immune-deficient seid mice and nude mice. Curr Top Microbiol Immunol 1989;152:259-63.
159. Nomura T, Takahama Y, Hongyo T, Inohara H, Takatera H, Fukushima H, Ishti Y, Hamaoka T. SCID (severe combined immunodeficiency) mice as a new system to investigate metastasis of human tumors. J Radiat Res 1990;31:288-92.
160. Nomura T, Takahama Y, Hongyo T, Takatera H, lnohara H, Fukushima H, Ono S, Hamaoka T. Rapid growth and spontaneous metastasis of human germinal tumors ectopically transplanted into SCID (severe combined immunodeficiency) and scid-nudestreaker mice. Jpn J Cancer Res 1991;82:701-9.
161. Inohara H, Matsunaga T, Nomura T. Growth and metastasis of fresh human benign and malignant tumors in the head and neck regions transplanted into SCID mice. Carcinogenesis 1992;13:845-9.
162. Fukuda K, Nakajima H, Taniguchi E, Sutoh K, Wang H, Hande PM, Li LY, Kurooka M, Mori K, Hongyo T, Kubo T, Nomura T. Morphology and function of human benign tumors and normal thyroid tissues maintained in severe combined immunodeficient mice. Cancer Lett 1998;132:153-8.
163. Iwanuma Y, Chen FA, Egilmez NK, Takita H, Bankert RB. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Res 1997;57:2937-42.
164. Williams SS, Chen FA, Kida H, Yokata S, Miya K, Kato M, Barcos MP, Wang HQ, Alosco T, Umemoto T, Croy BA, Repasky EA, et al. Engraftment of hitman tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. J Immunol 1996;156:1908-15.
165. Bankert RB, Umemoto T, Sugiyama Y, Chen FA, Repasky E, Yokota S. Human lung tumors, patients' peripheral blood lymphocytes and tumor infiltrating lymphocytes propagated in SCID mice. Curr Top Microbiol Immunol 1989;152:201-10.
166. Kuriakose MA, Chen FA, Egilmez NK, Jong YS, Mathiowitz E, DeLacure MD, Hicks WL Jr., Loree TL, Bankert RB. Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model. Head Neck 2000;22:57-63.